The methods many countries use to evaluate new medicines significantly underestimate the true societal benefits of innovative treatments. When high-income countries use traditional methods as a bargaining tool to deny coverage and/or secure lower prices, they free ride on the R&D investments of others and reduce patient access to novel medicines in their own countries.

Beneficiaries say Inflation Reduction Act will worsen access, affordability challenges.

A new survey demonstrates that a majority of consumers want health plans to lower out-of- pocket costs, but are concerned state government price controls will harm access and not reduce costs

The omission of assumptions about genericization means that CEAs may misrepresent the long run opportunity costs for drugs. The field needs clearer guidance for when CEAs should account for genericization, and for the inclusion of other price dynamics that might influence a drug’s cost-effectiveness.